The EU agency revealed AstraZeneca vaccine might have a connection to very limited blood clots. However, the health department suggested continuing inoculation and counterbalancing the risk factors.
The European Agency reported that they keep saying healthcare experts and spreading awareness among rare side effect. Along with platelets count gets lower within 14 days of vaccination.
Specific age group facing unusual side effects like blood clots
Women below 60 years have faced specific blood clots within 14 days of injection. However, based on recent data, the health department didn’t approve the risk factors.
TET has reached out to AstraZeneca for a remark. Previously WHO affirmed that vaccines are completely risk-free and no blood clots are occurring because of the vaccine.
European Medical Agency reconsiders multiple cases emerging from the UK and Europe zone. From this region, approximately more than 20 million inoculated with the AstraZeneca vaccine.
Cooke, the EMA director, said the mortality rate of Covid-19 is higher than the mortality rate from vaccine reactions. The recorded incidents of rare blood clots after receiving the AstraZeneca vaccine define as a reaction of the inoculation – Cooke added.
European countries suspends inoculation
The previous month, several European countries, like Spain, Germany, France, and Italy, stopped using the AstraZeneca vaccine after occurring blood clots. Multiple death cases have occurred after vaccination. Thus, specific countries have restrained vaccinations in senior citizens.
Marco Cavaleri, the EMA chairperson, stated the research couldn’t find any proper reason for this unusual side effect.
Cavaleri told the Italian press that there was a link between vaccination and rare blood clots. But the proper reason for the reaction is still unknown.
Vaccine developers Oxford University and AstraZeneca have restricted research of the vaccine in minors. The United Kingdom examines the association of blood clots with the vaccine in full-grown people.
The Castile and Leòn area in Spain has restrained the shot temporarily. Further, Veronica Casado, zonal health executive, said that she decided this after contacting the minister of health.
Casado added that medical experts should reevaluate the usage of the vaccine. Based on which age group faces higher blood clot risk, the use of the shot should be restricted. There is no doubt in AstraZeneca’s research. Moreover, it is important for all vaccines to reach out to more than 60 % of the youth population.